TY - JOUR
T1 - A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort
AU - Pedrini, Steve
AU - Gupta, Veer B.
AU - Hone, Eugene
AU - Doecke, James
AU - O'Bryant, Sid
AU - James, Ian
AU - Bush, Ashley I.
AU - Rowe, Christopher C.
AU - Villemagne, Victor L.
AU - Ames, David
AU - Masters, Colin L.
AU - Martins, Ralph N.
AU - Savage, Greg
AU - Wilson, Bill
AU - Bourgeat, Pierrick
AU - Fripp, Jurgen
AU - Gibson, Simon
AU - Leroux, Hugo
AU - McBride, Simon
AU - Salvado, Olivier
AU - Fenech, Michael
AU - Francois, Maxime
AU - Barnes, Mary
AU - Baker, Jenalle
AU - Barnham, Kevin
AU - Bellingham, Shayne
AU - Bomke, Julia
AU - Pejoska, Sveltana Bozin
AU - Buckley, Rachel
AU - Cheng, Lesley
AU - Collins, Steven
AU - Cooke, Ian
AU - Cyarto, Elizabeth
AU - Darby, David
AU - Dore, Vincent
AU - El-Sheikh, Denise
AU - Faux, Noel
AU - Fowler, Christopher
AU - Harrington, Karra
AU - Hill, Andy
AU - Horne, Malcolm
AU - Jones, Gareth
AU - Kamer, Adrian
AU - Killeen, Neil
AU - Korrel, Hannah
AU - Lamb, Fiona
AU - Lautenschlager, Nicola
AU - Lennon, Kate
AU - Li, Qiao Xin
AU - Lim, Yen Ying
AU - Louey, Andrea
AU - Macaulay, Lance
AU - Mackintosh, Lucy
AU - Maruff, Paul
AU - McIlroy, Alissandra
AU - Nigro, Julie
AU - Perez, Kayla
AU - Pertile, Kelly
AU - Restrepo, Carolina
AU - Cardoso, Barbara Rita
AU - Rembach, Alan
AU - Roberts, Blaine
AU - Robertson, Jo
AU - Rumble, Rebecca
AU - Ryan, Tim
AU - Sach, Jack
AU - Silbert, Brendan
AU - Thai, Christine
AU - Trounson, Brett
AU - Volitakis, Irene
AU - Vovos, Michael
AU - Ward, Larry
AU - Watt, Andrew
AU - Williams, Rob
AU - Woodward, Michael
AU - Yates, Paul
AU - Ugarte, Fernanda Yevenes
AU - Zhang, Ping
AU - Bird, Sabine
AU - Brown, Belinda
AU - Burnham, Samantha
AU - Chatterjee, Pratishtha
AU - Cox, Kay
AU - Fernandez, Shane
AU - Fernando, Binosha
AU - Gardener, Sam
AU - Laws, Simon
AU - Lim, Florence
AU - Lim, Lucy
AU - Tegg, Michelle
AU - Lucas, Kathy
AU - Martins, Georgia
AU - Porter, Tenielle
AU - Rainey-Smith, Stephanie
AU - Rodrigues, Mark
AU - Shen, Kaikai
AU - Sohrabi, Harmid
AU - Taddei, Kevin
AU - Taddei, Tania
AU - Tan, Sherilyn
AU - Verdile, Giuseppe
AU - Weinborn, Mike
AU - Farrow, Maree
AU - Frost, Shaun
AU - Hanson, David
AU - Hor, Maryam
AU - Kanagasingam, Yogi
AU - Leifert, Wayne
AU - Lockett, Linda
AU - Riley, Malcolm
AU - Saunders, Ian
AU - Thomas, Philip
AU - The AIBL Research Group
N1 - Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ϵ4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ϵ4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.
AB - Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ϵ4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ϵ4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.
UR - http://www.scopus.com/inward/record.url?scp=85032174892&partnerID=8YFLogxK
U2 - 10.1038/s41598-017-14020-9
DO - 10.1038/s41598-017-14020-9
M3 - Article
C2 - 29070909
AN - SCOPUS:85032174892
VL - 7
SP - 1
EP - 12
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 14057
ER -